TOMM7: A Potential Drug Target and Biomarker (G54543)

Target Name: TOMM7

NCBI ID: G54543

TOMM7

TOMM7: A Potential Drug Target and Biomarker

TOMM7, short for Tissue-Specific Oligomeric Mucin 7, is a protein that is expressed in various tissues and organs, including the brain, lungs, heart, and liver. It is a member of the TOMM family, which includes TOMM4 and TOMM5, and is characterized by the presence of a unique N-terminal oligomerization. TOMM7 has been identified as a potential drug target and biomarker due to its unique structure and expression pattern in various tissues.

The TOMM family is characterized by the presence of a unique N-terminal oligomerization, which is a type of protein structure where multiple amino acids are linked together in a specific order. This structure is unique among proteins and has been implicated in various biological processes, including cell signaling and tissue organization. The N-terminal oligomerization of TOMM7 is a unique feature that has not been observed in other proteins, which makes it an attractive target for drug development.

In addition to its unique structure, TOMM7 has also been identified as a potential drug target due to its expression pattern in various tissues. TOMM7 is expressed in various tissues, including the brain, lungs, heart, and liver, and has been shown to play a role in various biological processes, including cell signaling, tissue organization, and inflammation. This suggests that TOMM7 may be a good candidate for drug targeting in these tissues.

Another potential mechanism by which TOMM7 may be a drug target is its role in the development and progression of various diseases, including cancer. TOMM7 has been shown to be involved in various cellular processes that are associated with cancer development, including cell signaling, migration, and invasion. Additionally, TOMM7 has been shown to be involved in the regulation of cell apoptosis, which is a process that is important for the elimination of damaged or dysfunctional cells.

In addition to its potential as a drug target, TOMM7 may also be a useful biomarker for the diagnosis and monitoring of various diseases. Its unique expression pattern and involvement in various cellular processes make it an attractive candidate for use as a biomarker in disease diagnostic tests. For example, TOMM7 has been shown to be involved in the development and progression of various diseases, including cancer, and may be used as a biomarker for the diagnosis and monitoring of these diseases.

In conclusion, TOMM7 is a protein that has unique structure and expression pattern, which makes it an attractive candidate for drug targeting and biomarker development. Its involvement in various cellular processes and its potential as a drug target and biomarker make it a promising target for further research and development. Further studies are needed to fully understand the role of TOMM7 in various biological processes and its potential as a drug target and biomarker.

Protein Name: Translocase Of Outer Mitochondrial Membrane 7

Functions: Required for assembly and stability of the TOM complex. Positive regulator of PRKN translocation to damaged mitochondria. Acts probably by stabilizing PINK1 on the outer membrane of depolarized mitochondria

The "TOMM7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOMM7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets